Anti-LIV-1/SLC39A6 Antibody ((ladiratuzumab vedotin)
Catalog No.
F1560
Anti-LIV-1/SLC39A6 Antibody ((ladiratuzumab vedotin)
Featured Products
Ladiratuzumab vedotin (SGN-LIV1A, anti-LIV-1 ADC) is an antibody-drug conjugate (ADC) consisting of a humanized anti-LIV-1 antibody conjugated to Monomethyl auristatin E (MMAE) via a proteolytically cleavable linker. Ladiratuzumab vedotin has the potential to be used in a variety of cancers.
Quality Control & DataSheet
- View current batch:
-
Purity > 95% by SDS-PAGE and SEC-HPLC analyses.
- MSDS (Material Safety Data Sheet)
- Datasheet
146.96 kDa
Dry ice
1629760-29-7
-80°C
2 years
Liquid
See label
For reconstitution, we recommend adding sterile, distilled water to achieve a final antibody concentration. Gently shake it to solubilize the protein completely. Do not vortex.
CHO
SGN-LIV1A, MK-6440
100 mM Pro 20 mM Arg pH 5.0. No preservative!
Q13433
Human
MMAE
Monoclonal
Protein A
IgG1
ELISA, FACS, Kinetics, Functional assay, Animal Model
Immobilized human LIV 1, His Tag at 2 ug/mL can bind Anti-LIV-1 / SLC39A6 Reference Antibody (Ladiratuzumab vedotin), EC50 is 0.007652 ug/mL.
LIV-1 / SLC39A6
Please avoid freeze-thaw cycles.